熱門資訊> 正文
Protara Therapeutics GAAP每股收益为-0.97美元
2024-05-02 20:49
- Protara Therapeutics press release (NASDAQ:TARA): Q1 GAAP EPS of -$0.97.
- cash, cash equivalents and investments in marketable debt securities totaled $55.2 million.
-
More on Protara Therapeutics
- Protara: A Bombed Out Biotech With A Very Positive Skew
- Protara Therapeutics jumps 23% on $45M oversubscribed private financing
- Seeking Alpha’s Quant Rating on Protara Therapeutics
- Historical earnings data for Protara Therapeutics
- Financial information for Protara Therapeutics
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。